Guttate Psoriasis clinical trials at UCSF
1 research study open to eligible people
Guttate psoriasis results in tiny, red, scaly spots on the skin. UCSF is evaluating how guselkumab affects patients with various types of psoriasis. This research looks at how genetic factors influence the treatment's outcomes.
Showing trials for
Guselkumab Immunogenetics
open to eligible people ages 18 years and up
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
San Francisco, California
Our lead scientists for Guttate Psoriasis research studies include Wilson Liao, MD.
Last updated: